Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 2/20 | 0.39 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.39 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.39 |
| ▸ | PCNA | P12004 | 1/20 | 0.39 |
| ▸ | LIG1 | P18858 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 2/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6092768 | 1.00 | CYP1A2 (0.48) | CYP1A2CYP3A4CYP2C9CYP2C19LOXL2 | |
| SCHEMBL5742009 | 1.00 | CYP1A2 (0.48) | CYP1A2CYP3A4CYP2C9CYP2C19LOXL2 | |
| Hydrochloric Acid SCHEMBL22264027 | 0.98 | CYP1A2 (0.47) | CYP1A2CYP3A4CYP2C9CYP2C19LOXL2 | |
| Hydrochloric Acid SCHEMBL21144792 | 0.98 | CYP1A2 (0.47) | CYP1A2CYP3A4CYP2C9CYP2C19LOXL2 | |
| Hydrochloric Acid SCHEMBL21144790 | 0.98 | CYP1A2 (0.47) | CYP1A2CYP3A4CYP2C9CYP2C19LOXL2 | |
| SCHEMBL5007558 | 0.82 | LOXL2 (0.52) | CYP1A2CYP3A4CYP2C9CYP2C19LOXL2 | |
| SCHEMBL5066649 | 0.81 | TAAR1 (0.53) | CYP1A2CYP3A4CYP2C9CYP2C19LOXL2 | |
| SCHEMBL6938911 | 0.80 | SLC6A4 (0.55) | CYP1A2CYP3A4CYP2C9CYP2C19LOXL2 | |
| SCHEMBL14860759 | 0.79 | PRKCI (0.63) | CYP3A4EPHX1 | |
| SCHEMBL8328921 | 0.78 | FDPS (0.53) | CYP1A2CYP3A4CYP2C9DPP4EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654818-B2 | Furane derivatives as inhibitors of ATAD2 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-19 | — | — | US | disclosed |
| EP-3383865-B1 | FURANE DERIVATIVES AS INHIBITORS OF ATAD2 | Bayer Pharma AG (DE) | 2020-01-29 | — | — | EP | disclosed |
| US-20190218196-A1 | FURANE DERIVATIVES AS INHIBITORS OF ATAD2 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-07-18 | — | — | US | disclosed |
| WO-2017093272-A1 | FURANE DERIVATIVES AS INHIBITORS OF ATAD2 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-08 | — | — | WO | disclosed |
| US-20060252780-A1 | Fused pyrimidine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-11-09 | — | — | US | disclosed |
| CN-1777608-A | fused pyrimidine derivatives | KYOWA HAKKO KOGYO KK (JP) | 2006-05-24 | — | — | CN | disclosed |
| EP-1637532-A1 | FUSED PYRIMIDINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-03-22 | — | — | EP | disclosed |
| US-7005430-B2 | Fused purine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-02-28 | — | — | US | disclosed |
| EP-1251130-B1 | FUSED PURINE DERIVATIVES | KYOWA HAKKO KOGYO KK (JP) | 2005-02-16 | — | — | EP | disclosed |
| US-20030176698-A1 | Fused purine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
| EP-1251130-A1 | FUSED PURINE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176698-A1 | Fused purine derivatives | PNP, NSUN2, CYP2W1 | CYP1A2 909/4885CYP3A4 1270/4885CYP2C9 403/4885 |
| US-20190218196-A1 | FURANE DERIVATIVES AS INHIBITORS OF ATAD2 | ATAD2, ATAD2B, TAF1L | CYP1A2 1559/4885CYP3A4 2947/4885CYP2C9 3177/4885 |
| US-20060252780-A1 | Fused pyrimidine derivatives | INSR, GPR119, NPY4R | CYP1A2 2679/4885CYP3A4 205/4885CYP2C9 2092/4885 |
| US-10654818-B2 | Furane derivatives as inhibitors of ATAD2 | ATAD2, ATAD2B, TAF1L | CYP1A2 1559/4885CYP3A4 2947/4885CYP2C9 3177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.